In the shadow of Munich’s high-tech clusters and Berlin’s bustling startup scenes, a subtler drama unfolds—one not marked by dramatic bankruptcies or fiery political debates, but by the slow, almost imperceptible erosion of what was once Europe’s biotechnological heartland. Germany, the land of Bayer, BASF, and the chemical-pharmaceutical giants that helped birth the modern life sciences, now confronts a leiser Untergang: a quiet waning of its biotech vitality. This is no sudden catastrophe, but a confluence of structural headwinds, cultural caution, and global power shifts that threaten to relegate German innovation to the footnotes of 21st-century biology.
Echoes of Industrial Glory
Germany’s biotech heritage runs deep, intertwined with its 19th-century chemical revolution. From Paul Ehrlich’s magic bullets in Frankfurt to the postwar reconstruction that positioned firms like Boehringer Ingelheim and Merck KGaA as pillars of European pharma, the country embodied methodical excellence. The Mittelstand—those nimble medium-sized enterprises—combined engineering precision with scientific rigor. Reunification and EU integration promised a new golden age: generous public funding, excellent universities (such as those in Munich, Heidelberg, and Berlin), and a robust manufacturing base. For a time, it delivered. BioNTech’s mRNA triumph during the pandemic briefly illuminated this legacy on the world stage.
Yet that moment of glory now feels like a high-water mark. The quiet decline began years earlier, masked by pandemic windfalls.
Concrete Signs of Erosion
Recent figures paint a portrait of stagnation. According to the EY German Biotechnology Report 2026, the sector raised €1.8 billion in capital in 2025—a 5% decline from the prior year. Venture capital investments fell sharply from nearly €900 million in 2024 to €601 million. Early-stage financing, crucial for nurturing new ideas, has collapsed. Total revenues reached around €12 billion, slightly down year-over-year.
BioNTech, the Mainz-based mRNA pioneer valued at around $28 billion at points in 2025, exemplifies the pressures. After its COVID success, the company announced closures of facilities in Idar-Oberstein, Marburg, and Tübingen, alongside shutting down its Berlin-based subsidiary JPT Peptide Technologies (affecting ~140 positions). These moves reflect a necessary sharpening toward late-stage oncology amid financing realities and post-pandemic market correction.
Evotec, the Hamburg-based drug discovery platform company (once a European flagship with a market cap around $1.5 billion in early 2025), has faced pipeline setbacks, partnership restructurings, and share price volatility. Its platform model, reliant on big pharma collaborations, highlights the vulnerability of mid-sized German players to shifting deal flows favoring faster-moving Chinese or better-capitalized US entities.
MorphoSys, the Munich antibody specialist acquired after years of development struggles, underscores another pattern: promising German assets often find their ultimate scale through foreign hands. Broader trends show talent and capital gravitating elsewhere. German biotechs struggle with scaling up compared to US counterparts, leading to reliance on international partners for late-stage development and commercialization.
No meaningful IPOs have materialized on German exchanges in recent years, contrasting with the vibrant NASDAQ pipeline for US biotechs. Clinical trial shares continue to drift away from Europe, while energy costs, regulatory hurdles, and a risk-averse investor mindset compound the issue.
Ethical and Cultural Undercurrents
This quiet decline carries a deeper ethical weight. Germany’s postwar identity forged in caution—Vorsicht as both virtue and vice—manifests in meticulous regulation (a strength in patient safety) and a societal aversion to speculative finance. This has preserved public trust but risks condemning the sector to irrelevance in a hyper-accelerated global race.
The ethical imperative is to balance prudence with boldness. When innovation emigrates, so do high-value jobs, tax revenues, and the ability to influence global standards on data ethics, equitable access, and responsible AI integration in drug discovery.
A Call Amid the Whisper
Germany retains formidable strengths: engineering depth, chemical manufacturing excellence, world-class research institutions, and companies like BioNTech that prove exceptional breakthroughs remain possible. Targeted reforms—enhanced early-stage funding, EU harmonization to reduce fragmentation, talent attraction policies, and a cultural shift toward embracing calculated risk—could spark renewal.
In the grand feuilleton of Europe’s pharmaceutical crossroads, German biotech is a central character. Its concrete struggles—funding drops at firms like Evotec, strategic retrenchments at BioNTech, and the steady outflow of ambition—mirror the continent’s dilemma: honoring humanistic and methodical traditions while competing against American capital markets and Chinese scale. The silence is deceptive. Louder reflection and decisive, concrete action are needed now—before the whispers of decline become the defining narrative of a once-vibrant sector.
